Cargando…

Alexander disease GFAP R239C mutant shows increased susceptibility to lipoxidation and elicits mitochondrial dysfunction and oxidative stress

Alexander disease is a fatal neurological disorder caused by mutations in the intermediate filament protein Glial Fibrillary Acidic Protein (GFAP), which is key for astrocyte homeostasis. These mutations cause GFAP aggregation, astrocyte dysfunction and neurodegeneration. Remarkably, most of the kno...

Descripción completa

Detalles Bibliográficos
Autores principales: Viedma-Poyatos, Álvaro, González-Jiménez, Patricia, Pajares, María A., Pérez-Sala, Dolores
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364016/
https://www.ncbi.nlm.nih.gov/pubmed/35933901
http://dx.doi.org/10.1016/j.redox.2022.102415
_version_ 1784765061517017088
author Viedma-Poyatos, Álvaro
González-Jiménez, Patricia
Pajares, María A.
Pérez-Sala, Dolores
author_facet Viedma-Poyatos, Álvaro
González-Jiménez, Patricia
Pajares, María A.
Pérez-Sala, Dolores
author_sort Viedma-Poyatos, Álvaro
collection PubMed
description Alexander disease is a fatal neurological disorder caused by mutations in the intermediate filament protein Glial Fibrillary Acidic Protein (GFAP), which is key for astrocyte homeostasis. These mutations cause GFAP aggregation, astrocyte dysfunction and neurodegeneration. Remarkably, most of the known GFAP mutations imply a change by more nucleophilic amino acids, mainly cysteine or histidine, which are more susceptible to oxidation and lipoxidation. Therefore, we hypothesized that a higher susceptibility of Alexander disease GFAP mutants to oxidative or electrophilic damage, which frequently occurs during neurodegeneration, could contribute to disease pathogenesis. To address this point, we have expressed GFP-GFAP wild type or the harmful Alexander disease GFP-GFAP R239C mutant in astrocytic cells. Interestingly, GFAP R239C appears more oxidized than the wild type under control conditions, as indicated both by its lower cysteine residue accessibility and increased presence of disulfide-bonded oligomers. Moreover, GFP-GFAP R239C undergoes lipoxidation to a higher extent than GFAP wild type upon treatment with the electrophilic mediator 15-deoxy-Δ(12,14)-prostaglandin J(2) (15d-PGJ(2)). Importantly, GFAP R239C filament organization is altered in untreated cells and is earlier and more severely disrupted than GFAP wild type upon exposure to oxidants (diamide, H(2)O(2)) or electrophiles (4-hydroxynonenal, 15d-PGJ(2)), which exacerbate GFAP R239C aggregation. Furthermore, H(2)O(2) causes reversible alterations in GFAP wild type, but irreversible damage in GFAP R239C expressing cells. Finally, we show that GFAP R239C expression induces a more oxidized cellular status, with decreased free thiol content and increased mitochondrial superoxide generation. In addition, mitochondria show decreased mass, increased colocalization with GFAP and altered morphology. Notably, a GFP-GFAP R239H mutant recapitulates R239C-elicited alterations whereas an R239G mutant induces a milder phenotype. Together, our results outline a deleterious cycle involving altered GFAP R239C organization, mitochondrial dysfunction, oxidative stress, and further GFAP R239C protein damage and network disruption, which could contribute to astrocyte derangement in Alexander disease.
format Online
Article
Text
id pubmed-9364016
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-93640162022-08-11 Alexander disease GFAP R239C mutant shows increased susceptibility to lipoxidation and elicits mitochondrial dysfunction and oxidative stress Viedma-Poyatos, Álvaro González-Jiménez, Patricia Pajares, María A. Pérez-Sala, Dolores Redox Biol Research Paper Alexander disease is a fatal neurological disorder caused by mutations in the intermediate filament protein Glial Fibrillary Acidic Protein (GFAP), which is key for astrocyte homeostasis. These mutations cause GFAP aggregation, astrocyte dysfunction and neurodegeneration. Remarkably, most of the known GFAP mutations imply a change by more nucleophilic amino acids, mainly cysteine or histidine, which are more susceptible to oxidation and lipoxidation. Therefore, we hypothesized that a higher susceptibility of Alexander disease GFAP mutants to oxidative or electrophilic damage, which frequently occurs during neurodegeneration, could contribute to disease pathogenesis. To address this point, we have expressed GFP-GFAP wild type or the harmful Alexander disease GFP-GFAP R239C mutant in astrocytic cells. Interestingly, GFAP R239C appears more oxidized than the wild type under control conditions, as indicated both by its lower cysteine residue accessibility and increased presence of disulfide-bonded oligomers. Moreover, GFP-GFAP R239C undergoes lipoxidation to a higher extent than GFAP wild type upon treatment with the electrophilic mediator 15-deoxy-Δ(12,14)-prostaglandin J(2) (15d-PGJ(2)). Importantly, GFAP R239C filament organization is altered in untreated cells and is earlier and more severely disrupted than GFAP wild type upon exposure to oxidants (diamide, H(2)O(2)) or electrophiles (4-hydroxynonenal, 15d-PGJ(2)), which exacerbate GFAP R239C aggregation. Furthermore, H(2)O(2) causes reversible alterations in GFAP wild type, but irreversible damage in GFAP R239C expressing cells. Finally, we show that GFAP R239C expression induces a more oxidized cellular status, with decreased free thiol content and increased mitochondrial superoxide generation. In addition, mitochondria show decreased mass, increased colocalization with GFAP and altered morphology. Notably, a GFP-GFAP R239H mutant recapitulates R239C-elicited alterations whereas an R239G mutant induces a milder phenotype. Together, our results outline a deleterious cycle involving altered GFAP R239C organization, mitochondrial dysfunction, oxidative stress, and further GFAP R239C protein damage and network disruption, which could contribute to astrocyte derangement in Alexander disease. Elsevier 2022-07-30 /pmc/articles/PMC9364016/ /pubmed/35933901 http://dx.doi.org/10.1016/j.redox.2022.102415 Text en © 2022 Consejo Superior de Investigaciones Científicas https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Viedma-Poyatos, Álvaro
González-Jiménez, Patricia
Pajares, María A.
Pérez-Sala, Dolores
Alexander disease GFAP R239C mutant shows increased susceptibility to lipoxidation and elicits mitochondrial dysfunction and oxidative stress
title Alexander disease GFAP R239C mutant shows increased susceptibility to lipoxidation and elicits mitochondrial dysfunction and oxidative stress
title_full Alexander disease GFAP R239C mutant shows increased susceptibility to lipoxidation and elicits mitochondrial dysfunction and oxidative stress
title_fullStr Alexander disease GFAP R239C mutant shows increased susceptibility to lipoxidation and elicits mitochondrial dysfunction and oxidative stress
title_full_unstemmed Alexander disease GFAP R239C mutant shows increased susceptibility to lipoxidation and elicits mitochondrial dysfunction and oxidative stress
title_short Alexander disease GFAP R239C mutant shows increased susceptibility to lipoxidation and elicits mitochondrial dysfunction and oxidative stress
title_sort alexander disease gfap r239c mutant shows increased susceptibility to lipoxidation and elicits mitochondrial dysfunction and oxidative stress
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364016/
https://www.ncbi.nlm.nih.gov/pubmed/35933901
http://dx.doi.org/10.1016/j.redox.2022.102415
work_keys_str_mv AT viedmapoyatosalvaro alexanderdiseasegfapr239cmutantshowsincreasedsusceptibilitytolipoxidationandelicitsmitochondrialdysfunctionandoxidativestress
AT gonzalezjimenezpatricia alexanderdiseasegfapr239cmutantshowsincreasedsusceptibilitytolipoxidationandelicitsmitochondrialdysfunctionandoxidativestress
AT pajaresmariaa alexanderdiseasegfapr239cmutantshowsincreasedsusceptibilitytolipoxidationandelicitsmitochondrialdysfunctionandoxidativestress
AT perezsaladolores alexanderdiseasegfapr239cmutantshowsincreasedsusceptibilitytolipoxidationandelicitsmitochondrialdysfunctionandoxidativestress